Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
118.97
-0.50 (-0.42%)
At close: Dec 20, 2024, 4:00 PM
119.30
+0.33 (0.28%)
After-hours: Dec 20, 2024, 5:02 PM EST
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 21 analysts with 12-month price forecasts for SRPT stock have an average target of 179.38, with a low estimate of 75 and a high estimate of 230. The average target predicts an increase of 50.78% from the current stock price of 118.97.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SRPT stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 7 | 6 |
| Buy | 10 | 11 | 11 | 12 | 13 | 13 |
| Hold | 3 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 18 | 18 | 18 | 20 | 22 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Reiterates $75 | Strong Sell | Reiterates | $75 | -36.96% | Dec 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Maintains $80 → $75 | Strong Sell | Maintains | $80 → $75 | -36.96% | Dec 3, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $200 → $182 | Buy | Maintains | $200 → $182 | +52.98% | Nov 27, 2024 |
| Needham | Needham | Strong Buy Maintains $205 → $202 | Strong Buy | Maintains | $205 → $202 | +69.79% | Nov 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Initiates $80 | Strong Sell | Initiates | $80 | -32.76% | Nov 25, 2024 |
Financial Forecast
Revenue This Year
1.87B
from 1.24B
Increased by 50.40%
Revenue Next Year
3.21B
from 1.87B
Increased by 71.44%
EPS This Year
2.24
from -5.80
EPS Next Year
11.77
from 2.24
Increased by 425.54%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.0B | 3.9B | 4.5B | |||
| Avg | 1.9B | 3.2B | 3.8B | |||
| Low | 1.7B | 2.3B | 1.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 59.4% | 111.1% | 41.7% | |||
| Avg | 50.4% | 71.4% | 19.3% | |||
| Low | 40.7% | 21.1% | -47.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.88 | 18.43 | 21.99 | |||
| Avg | 2.24 | 11.77 | 14.41 | |||
| Low | 1.55 | 7.09 | 8.60 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 722.7% | 86.7% | |||
| Avg | - | 425.5% | 22.3% | |||
| Low | - | 216.2% | -26.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.